Vertex Pharmaceuticals clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 1 with a minor change only.

1. Notable

   VX-272 in Healthy Participants

   Primary endpoint(s) modified

   Also in this update: Primary and study completion pushed from Mar 23, 2027 to Jun 26, 2027; Enrollment increased: 128 → 160 participants

   Vertex Pharmaceuticals Incorporated·Phase 1· NCT07437105· Registry history of NCT07437105 on ClinicalTrials.gov (opens the registry)

   Updated Sep 23, 2026

2. Notable

   Treatment With Povetacicept · Immunoglobulin A Nephropathy

   Enrolling by invitation only

   Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 18, 2026 to Sep 17, 2026

   Vertex Pharmaceuticals Incorporated·Phase 3· NCT07807995· Registry history of NCT07807995 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

3. Notable

   Povetacicept · Autoimmune Cytopenias (RUBY-4)

   Sponsor changed: Alpine Immune Sciences, Inc. to Alpine Immune Sciences Inc, A Subsidiary of Vertex

   Also in this update: Trial completed; Interventions modified

   Alpine Immune Sciences Inc, A Subsidiary of Vertex·Phase 1/2· NCT05757570· Registry history of NCT05757570 on ClinicalTrials.gov (opens the registry)

   Updated Sep 14, 2026

4. Notable

   VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

   Recruitment opened

   Vertex Pharmaceuticals Incorporated·Phase 1· NCT07792408· Registry history of NCT07792408 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.